Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 16/20 | 0.70 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.67 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16463797 | 0.97 | HCRTR1 (0.71) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL16463794 | 0.97 | HCRTR1 (0.71) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL2721615 | 0.89 | GRM5 (0.75) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL2722074 | 0.86 | GRM5 (0.61) | GRM5 | |
| SCHEMBL5332345 | 0.86 | GRM5 (0.71) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL28780313 | 0.85 | GRM5 (0.80) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL16464305 | 0.85 | GRM5 (0.61) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL16464304 | 0.85 | GRM5 (0.61) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL2722960 | 0.85 | GRM5 (0.70) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL5333513 | 0.84 | GRM5 (0.94) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630135-B1 | 1-(HETEROCYCLIC CARBONYL) PIPERIDINES | BAYER IP GMBH (DE) | 2020-03-04 | — | — | EP | claimed |
| US-20130261155-A1 | 1-(HETEROCYCLIC CARBONYL) PIPERIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | US | claimed |
| EP-2630135-A1 | 1-(HETEROCYCLIC CARBONYL) PIPERIDINES | Bayer Intellectual Property GmbH (DE) | 2013-08-28 | — | — | EP | claimed |
| WO-2012052489-A1 | 1-(HETEROCYCLIC CARBONYL) PIPERIDINES | BAYER CROPSCIENCE AG (DE) | 2012-04-26 | — | — | WO | claimed |
| EP-2630135-B1 | 1-(HETEROCYCLIC CARBONYL) PIPERIDINES | BAYER IP GMBH (DE) | 2020-03-04 | — | — | EP | disclosed |
| US-9545105-B2 | 1-(heterocyclic carbonyl) piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-01-17 | — | — | US | disclosed |
| US-20130261155-A1 | 1-(HETEROCYCLIC CARBONYL) PIPERIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261155-A1 | 1-(HETEROCYCLIC CARBONYL) PIPERIDINES | CBR3, CBR1, CYP51A1 | GRM5 1881/4885HCRTR1 2648/4885HCRTR2 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.